Macro Group Pharmaceutical S.A.E. (Macro Capital) is specialized in developing, manufacturing and marketing pharmaceuticals. The company's products include anti-scar, skincare, antiseptic, hair care, oral care and muscle relaxant medicines. In addition, the group offers plant-based medicines. At the end of 2021, Macro Group Pharmaceutical S.A.E. (Macro Capital) had one production site in Egypt.

Employees

-

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/26/23	EGP 1.220	-0.81%	1,59,98,800
22/26/22	EGP 1.230	-0.81%	1,32,74,780
21/26/21	EGP 1.240	0.00%	1,76,17,136
17/26/17	EGP 1.240	0.00%	4,09,57,420
16/26/16	EGP 1.240	0.00%	3,74,99,670

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

End-of-day quote Egyptian Exchange Other stock markets 23/06/2026			5-day change	1st Jan Change
1.220 ^EGP	-0.81%		-1.61%	+7.02%

17/05	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
20/02	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	70Cr 1.4Cr 1.23Cr 1.13Cr 1.06Cr 1.99Cr 132.53Cr 2.02Cr 14Cr 5.26Cr 65Cr 5.25Cr 5.14Cr 226.01Cr	P/E 2026 *	20.3x	P/E 2027 *	13.6x
Enterprise Value	62Cr 1.24Cr 1.09Cr 1Cr 93.87L 1.76Cr 117.35Cr 1.79Cr 12Cr 4.66Cr 58Cr 4.65Cr 4.55Cr 200.12Cr	EV / Sales 2026 *	0.52x	EV / Sales 2027 *	0.38x
Free-Float	95.08%	Yield 2026 *	2.46%	Yield 2027 *	3.28%

17/05	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
20/02	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
19/02	Macro Group Pharmaceutical FY consol profit EGP 115.7 mln	RE
19/11	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	Macro Group Pharmaceutical nine-month consol loss EGP 66.1 million	RE
12/25/12	Macro Group Pharmaceutical shareholders approve authorized capital increase to EGP 3 billion	RE
21/25/21	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/25/21	Macro Group Pharmaceutical posts Q2 consol profit EGP 46.5 mln	RE
21/25/21	Macro Group Pharmaceutical board approves renewal of EGP 100 mln short-term financing from KFH	RE
22/25/22	Macro Group Pharmaceutical board proposes capital increase	RE
10/25/10	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/25/10	MACRO Group Pharmaceutical's 328.6 Million Shares Block Traded For EGP 631 Million - EGX	RE
27/25/27	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	-0.81%
1 week	-1.61%
Current month	-2.40%
3 months	-10.29%
6 months	+8.93%
Current year	+7.02%

Macro Group Pharmaceuticals (Macro Capital) S.A.E Share Price

Stocks

MCRO

EGS7D971C011

Pharmaceuticals

Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Chart: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Latest news : Macro Group Pharmaceuticals (Macro Capital) S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	1.21	1.27
1 month	1.2	1.31
Current year	1.02	1.68
1 year	0.81	4.11
3 years	0.81	4.11
5 years	0.81	5.28
10 years	0.81	5.28

Manager	Title	Age	Since
Khaled Kamel CEO	Chief Executive Officer	-	-
Zeina Shahin IRC	Investor Relations Contact	-	-
Tamer Raouf SAM	Sales & Marketing	-	01/01/2022

Director	Title	Age	Since
Sahar El-Sallab BRD	Director/Board Member	-	01/01/2021
Ahmed Badreldin BRD	Director/Board Member	54	01/01/2021
Ahmed El-Nayeb CHM	Chairman	-	01/01/2002

	2026 *	2027 *
Net sales	119Cr 2.39Cr 2.1Cr 1.94Cr 1.81Cr 3.4Cr 226.72Cr 3.46Cr 23Cr 9Cr 111.24Cr 8.98Cr 8.79Cr 386.62Cr	155.2Cr 3.12Cr 2.74Cr 2.53Cr 2.37Cr 4.43Cr 295.69Cr 4.51Cr 30Cr 12Cr 145.08Cr 12Cr 11Cr 504.24Cr
Net income	21Cr 41.43L 36.4L 33.54L 31.4L 58.82L 39Cr 59.81L 4.03Cr 1.56Cr 19Cr 1.56Cr 1.52Cr 67Cr	28Cr 56.92L 50L 46.07L 43.13L 80.81L 54Cr 82.17L 5.53Cr 2.14Cr 26Cr 2.14Cr 2.09Cr 92Cr
Net Debt	-7.97Cr -16.03L -14.08L -12.98L -12.15L -22.76L -15Cr -23.14L -1.56Cr -60.31L -7.45Cr -60.17L -58.88L -26Cr	-11Cr -22.12L -19.44L -17.91L -16.76L -31.41L -21Cr -31.94L -2.15Cr -83.24L -10Cr -83.05L -81.26L -36Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	-0.81%	-1.61%	-39.00%	-58.50%	1.41Cr
ELI LILLY AND COMPANY	+0.45%	-1.37%	+43.66%	+141.28%	98TCr
JOHNSON & JOHNSON	+3.37%	+1.66%	+58.00%	+44.48%	56TCr
ABBVIE INC.	+2.07%	+5.52%	+27.75%	+72.72%	41TCr
ROCHE HOLDING AG	+1.53%	-1.93%	+23.33%	+16.35%	31TCr
ASTRAZENECA PLC	+2.26%	+2.95%	+30.77%	+17.16%	27TCr
NOVARTIS AG	+2.61%	+2.66%	+30.07%	+37.04%	27TCr
NOVO NORDISK A/S	+2.60%	+7.76%	-35.32%	-43.32%	20TCr
AMGEN INC.	+0.66%	-0.24%	+27.37%	+52.79%	19TCr
GILEAD SCIENCES, INC.	+0.14%	-1.71%	+17.76%	+61.42%	16TCr
Average	+1.53%	-0.99%	+18.44%	+34.14%	33.5TCr
Weighted average by Cap.	+1.68%	-2.22%	+33.15%	+66.74%